Clinical Trial Search

Primary: Focal Segmental Glomerulosclerosis Permeability Factor (FSPF) — 0.69; 0.35 Palb — p=0.009

Primary: Maximum Tolerated Dose (MTD) or Maximum Feasible Dose — NA mg/kg

Primary: Absolute Change From Baseline in Independent Photography Review (IPR-V3 Score) — -0.80; -1.30; -1.11 score

Primary: Probable Benefit Measures as Successful Aneurysm Treatment With the LVIS™ Device, as Measured by Aneurysm Angiographic Occlusion of ≥ 90% at 6 Months (± 4 Weeks) — 95…

Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants

Primary: Level of Pain During Specific Time Intervals Throughout D&C Procedure. — 52.2; 51.7; 33.6; 32.7 mm — p=0.94

Primary: Safety Events — 20; 0; 40; 50 percentage of patients

Primary: Time-to-Treatment Failure (Intent-To-Treat Analysis) — 4.9; 2.7; 2.2; 3.7 months

Primary: Pearl Index, by Treatment Group — 1.92; 3.12 Pregnancies per 100 woman-years — p=0.531

Primary: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) According to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0…

Primary: Treatment Failures — 9; 4 participants — p=0.25

Primary: Visual Acuity of the Study Eye: Average Change From Baseline to Month 1 Through Month 12 — 62.3; 64.1; 65.1; 68.25 Letters

Primary: First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in…

Primary: CDR Power of Attention — 1262.1744; 1252.9510 msec

Primary: Compare Periprosthetic Bone Mineral Density (BMD), at 1y Postoperative, in Patients That Have Undergone a Total Hip Arthroplasty (THA) Via the Direct Anterior Approach…